Ozempic Face: Why GLP-1 Weight Loss Changes Your Face and What Can Limit It

"Ozempic face" is a popular name for the sunken cheeks, hollow eyes, and loose or sagging skin that some people notice after losing a lot of weight on GLP-1 drugs such as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound). It is not a medical diagnosis, and it is not unique to Ozempic. Similar changes are described after bariatric surgery and other large weight losses.

The best measurement so far comes from a 2025 study at Vanderbilt University Medical Center. Using head scans taken before and during GLP-1 treatment in 20 patients, researchers found that midface volume fell by a median of 9%. On average, people lost about 7% of their midface volume for every 10 kg (about 22 pounds) of body weight lost.

A review published in Aesthetic Surgery Journal in October 2026 pulled together 46 reports and reached a plain conclusion: most of what people call Ozempic face is the face deflating as fat is lost, on top of normal aging. There is no proven way to prevent it completely, and the evidence for cosmetic treatments is still limited. For most people with obesity, the health benefits of weight loss matter far more than these changes, so talk with your prescriber before changing or stopping a medicine.

The face holds fat in separate pockets called fat compartments. Some sit just under the skin, in what is called subcutaneous fat, and some sit deeper, closer to the bone. These pads give the cheeks, temples, and the area under the eyes their fullness and help hold the skin up.

When the body burns fat, the face loses some too. In the Vanderbilt study, the superficial compartments shrank more than the deep ones: a median of 11% compared with 7%. Superficial volume loss tracked closely with how much weight a person lost, while deep volume loss did not.

Skin does not always shrink back to fit. Skin gets its firmness from collagen, a protein that acts like scaffolding, and from elastic fibers. Both decline with age and with sun damage. So when the fat underneath shrinks, older or sun-damaged skin is more likely to sag or fold. That is why the same amount of weight loss can look very different on a 30-year-old and a 60-year-old.

Only a few studies have measured these changes directly, and all of them are small or rely on self-reports.

The Vanderbilt study, published in Otolaryngology-Head and Neck Surgery in 2025, searched hospital records for patients who had CT or MRI scans of the head both before and after starting a GLP-1 drug. Twenty patients qualified. Their median age was 54, they took the drug for an average of about 10 and a half months, and they lost an average of 11 kg. The authors called it one of the first measurements of the Ozempic face effect, and because it used scans taken for other reasons, it could not control for everything else going on in these patients' lives.

Surveys add the patient's view. In a survey of 504 U.S. adults using GLP-1 or GLP-1/GIP drugs, conducted in mid-2025 and published in the Journal of Cosmetic Dermatology in 2026 by researchers at L'Oréal, 38.7% reported some skin change. The most common were facial volume loss (10.9%), sagging (8.3%), and jowls (7.7%), and these changes were more often reported by people over 55 and by those who had lost more than 20 pounds. The Aesthetic Surgery Journal review also describes a survey of 1,226 people in which facial volume loss and looseness were reported more often by those who lost a greater share of their body weight.

Researchers have also built a way to measure how people feel about these changes. In 2026, a team led from McMaster University created a 15-item version of the FACE-Q questionnaire, a standard survey of satisfaction with facial appearance, and tested it in 632 people who wanted to use, were using, or had used a GLP-1 drug for weight loss. Tools like this should make future treatment studies easier to compare.

The evidence points to three factors, mostly from surveys and the small imaging study.

The first is the amount of weight lost. In the imaging study, more weight loss meant more superficial facial volume loss, and in the surveys, people who lost more weight reported more facial changes.

The second is age. Survey respondents over 55 reported skin changes more often, which fits with the loss of collagen and elastic fibers that comes with aging.

The third is starting anatomy. The Aesthetic Surgery Journal review describes the changes as deflation layered on each person's existing facial structure and aging, so the same weight loss will not look the same on everyone.

What is less clear is the role of speed. Many articles blame rapid weight loss, but the Aesthetic Surgery Journal review found that the separate effect of how fast weight comes off has not been established, and the roles of menopause and hormone therapy are also uncertain. There is no good evidence that the drug itself damages facial fat in a way that other forms of weight loss do not.

No study has tested a prevention plan for Ozempic face, so the steps below are reasonable but unproven for the face itself.

Agree on a weight goal and pace with your prescriber. Because facial volume loss tracks with the amount of weight lost, a target based on your health needs, rather than the lowest number possible, may matter. Ask about dose increases if side effects or very fast loss are a concern.

Protect your muscle and overall health. Eating enough protein and doing resistance training, such as lifting weights, help preserve lean mass, meaning muscle and other tissue that is not fat, during GLP-1 weight loss. No study shows that this protects facial fat specifically, but it supports strength and metabolism while you lose weight. Our guide to protein and resistance training on GLP-1s covers the details.

Protect your skin. The American Academy of Dermatology recommends daily broad-spectrum, water-resistant sunscreen with SPF 30 or higher on uncovered skin, and it notes that smoking greatly speeds up skin aging. These steps help preserve the collagen that keeps skin firm. Creams sold for this purpose, including peptide creams, have little evidence behind them for weight-loss-related sagging; our review of peptides for wrinkles explains what has and has not been tested.

Be wary of quick fixes. Drinking extra water does not restore lost facial fat, and supplements marketed against Ozempic face have not been shown to work.

Several cosmetic treatments are used to restore volume or tighten skin, but the Aesthetic Surgery Journal review found that the evidence for them in GLP-1 users is limited and mostly comes from small studies without comparison groups.

Dermal fillers are gels injected under the skin to add volume. The most common are made of hyaluronic acid, a substance the body makes naturally. Others, called biostimulators, such as poly-L-lactic acid or calcium hydroxylapatite, are meant to prompt the skin to make new collagen over time. In a 2026 case series of 15 women in Latin America who had lost about 18% of their weight on GLP-1 drugs, a combination of poly-L-lactic acid and hyaluronic acid fillers improved ratings of sagging and wrinkles after about three months. A 2025 case series of four patients reported that a diluted calcium hydroxylapatite filler kept lower-face volume stable during weight loss. Studies this small cannot show how well these treatments work for most people.

In a 2026 survey of 406 aesthetic practitioners published in Dermatologic Surgery, midface volume loss and loose skin of the face and neck were the changes they saw most often in GLP-1 patients, and hyaluronic acid fillers were the treatment they chose most often for facial concerns. Other options include moving a patient's own fat to the face, called fat grafting, energy-based skin tightening, and facelift surgery.

Fillers carry real risks. The FDA says the most concerning one is accidental injection into a blood vessel, which has caused tissue death, vision problems including blindness, and stroke. The agency warns against buying fillers online and says needle-free devices are not approved for injecting them. Choose a licensed, experienced clinician, and ask whether it makes sense to wait until your weight is stable.

For people with obesity, GLP-1 drugs lower blood sugar and weight, and some have proven heart, kidney, or sleep apnea benefits. Facial changes are a real concern for many patients, and they deserve to be taken seriously, but they are a side effect of losing weight, not a sign that the drug is harming you. If the changes bother you, raise them with your prescriber rather than stopping the medicine on your own, since stopping usually leads to weight regain.

GLP-1 drugs can bring other visible changes, too. Our guides cover hair loss and nail changes and muscle loss during GLP-1 treatment.

Questions to ask your clinician:

• What weight target makes sense for my health, and how fast should I aim to lose it?
• How much protein should I eat, and what exercise do you recommend while I am on this drug?
• If I want cosmetic treatment, should I wait until my weight is stable?
• Who in my area is qualified to give fillers or other treatments safely?